On June 12, according to documents disclosed by Hong Kong Stock Exchange on June 12, Jianxin Yang increased its shareholding on June 6 at an average price of HKD 1.205 per share for 200,000 ordinary shares worth approximately HKD 241,000. After the increase, Jianxin Yang's latest shareholding number increased from 6,407.43 million shares to 4.99% from 4.97%.$CSTONE PHARMA-B (02616.HK)$The value of 200,000 common shares is approximately HKD 241,000. After the increase, Jianxin Yang's latest shareholding number is 6,407.43 million shares, and the warehouse-to-basket ratio has increased from 4.97% to 4.99%.
Supplementary information: Box 28: These shares represent limited stock units and stock options, granted to or to be issued to Dr. Yang under the pre-IPO rsu Scheme, pre-IPO share option scheme, and post-IPO incentive plan, respectively. On January 16, 2019, a total of 3,237,580 limited stock units granted to Dr. Yang were all vested by February 16, 2023.What is equity disclosure?
According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the company's shares) must disclose their shareholding in the listed company. Directors and senior executives of the listed company must disclose their shareholding and equity certificate rights in the listed company and any related companies.
Why is equity disclosure important?
Equity disclosure enables investors to identify (1) individuals who control or have the ability to control the shareholding of the listed company and (2) individuals who may benefit from transactions involving entities related to the listed company.